Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kohl's Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Kohl's Corporation trades at $16.87 (market cap $1.91B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 20.9× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.98% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KSS | |
|---|---|---|
Market Cap | $39.89B | $1.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $24.71 |
52-Week Low | $278.09 | $9.27 |
Enterprise Value | $38.15B | $8.01B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Kohl's (KSS) trades at $16.80, up 3.0% today, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten expectations, with Q1 2026 showing early turnaround progress, but revenue has declined from $19.4B in 2022 to $16.2B in 2025. The stock is undervalued with a P/E of 7.06 and P/B of 0.47, while analyst sentiment is cautious with a consensus price target of $16.75.
The outlook hinges on Kohl's ability to stabilize sales through proprietary brands and cost controls, but risks include persistent revenue declines and competitive pressures. Upside potential exists if turnaround efforts gain traction, yet investor caution is warranted given weak technicals and mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
